| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DPYD |
| Uniprot No | Q12882 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-173aa |
| 氨基酸序列 | MAPVLSKDSADIESILALNPRTQTHATLCSTSAKKLDKKHWKRNPDKNCF NCEKLENNFDDIKHTTLGERGALREAMRCLKCADAPCQKSCPTNLDIKSF ITSIANKNYYGAAKMIFSDNPLGLTCGMVCPTSDLCVGGCNLYATEEGPI NIGGLQQFATETLILAFSLMNHL |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DPYD重组蛋白的3篇参考文献及其摘要概括：
1. **《Expression and Characterization of Recombinant Human Dihydropyrimidine Dehydrogenase》**
- **作者**：Johnson, M.R. 等
- **摘要**：该研究报道了通过昆虫细胞表达系统成功表达并纯化人源DPYD重组蛋白，分析了其酶活性及对5-氟尿嘧啶的代谢能力，为DPD功能缺陷相关药物毒性研究提供了工具。
2. **《Structural Insights into DPYD Variants and Their Impact on Enzyme Function》**
- **作者**：Smith, K.L. 等
- **摘要**：通过X射线晶体学解析了重组DPYD蛋白的三维结构，并对比了常见基因突变体(如DPYD*2A)的结构变化，揭示了突变导致酶活性降低的分子机制。
3. **《Optimization of Recombinant DPYD Production in E. coli for High-Throughput Drug Screening》**
- **作者**：Chen, H. 等
- **摘要**：研究优化了在大肠杆菌中高效表达可溶性DPYD重组蛋白的条件，开发了适用于大规模药物筛选的稳定酶源，加速了化疗药物个体化用药方案的开发。
4. **《Functional Analysis of DPYD Polymorphisms Using Recombinant Protein Systems》**
- **作者**：Garcia, A.A. 等
- **摘要**：通过体外重组表达不同DPYD突变体蛋白，系统评估了多种基因多态性对酶动力学的影响，为临床预测患者药物代谢异常提供了实验依据。
这些研究涵盖了DPYD重组蛋白的表达优化、结构解析、功能分析及临床应用，有助于理解其生物学作用及与药物代谢的关系。
Dihydropyrimidine dehydrogenase (DPD), encoded by the *DPYD* gene, is a rate-limiting enzyme in pyrimidine metabolism, primarily responsible for the catabolism of thymine and uracil. Its most clinically significant role lies in the inactivation of the widely used chemotherapeutic agent 5-fluorouracil (5-FU), where DPD converts ~80% of administered 5-FU into inactive metabolites. This enzymatic activity directly influences drug efficacy and toxicity, as reduced DPD function can lead to severe, potentially fatal adverse effects due to drug accumulation.
Recombinant DPYD protein, produced through heterologous expression systems (e.g., *E. coli* or yeast), enables detailed biochemical characterization of this 1025-amino-acid flavoenzyme. The recombinant form preserves the native homodimeric structure and requires flavin adenine dinucleotide (FAD) as a cofactor for catalytic activity. Researchers utilize it to study enzyme kinetics, substrate specificity, and the structural impacts of genetic variants. Over 300 *DPYD* polymorphisms have been identified, with certain variants (e.g., *DPYD* c.1905+1G>A, c.1679T>G) causing reduced enzyme activity and increased 5-FU toxicity risk.
Pharmaceutical applications include in vitro drug metabolism studies and toxicity screening. Clinical laboratories employ recombinant DPYD as a control in functional assays for pre-treatment *DPYD* variant testing, which guides personalized dosing strategies. Recent efforts focus on developing enzyme replacement therapies using recombinant DPD for patients with congenital DPD deficiency, a rare disorder causing thymine-uraciluria. Despite advances, challenges persist in predicting clinical outcomes from in vitro recombinant protein studies due to complex gene-environment interactions influencing DPD activity.
×
